Notice 20 Jun 2025 commerce, nist, quality management, performance excellence, baldrige award, business improvement

🏆Information Collection Notice for Malcolm Baldrige National Quality Award

The Department of Commerce, in accordance with the Paperwork Reduction Act of 1995 (PRA), invites the general public and other Federal agencies to comment on proposed, and continuing information collections, which helps us assess the impact of our information collection requirements and minimize the public's reporting burden. The purpose of this notice is to allow for 60 days of public comment preceding submission of the collection to OMB.

Learn More
Notice 10 Jun 2025 nist, performance evaluation, quality management, malcolm baldrige award, business excellence

🏆Judges Panel Meeting for Malcolm Baldrige Award 2025

The Judges Panel of the Malcolm Baldrige National Quality Award (Judges Panel) reports the results of the Malcolm Baldrige National Quality Award (Award) activities to the Director of the National Institute of Standards and Technology (NIST) each year, along with its recommendations for the improvement of the Award process. The purpose of this meeting is to discuss the 2025 Baldrige Award process, including the identification of which award applicant organizations should be advanced to the site visit phase. The meeting is closed to the public in order to protect the proprietary data to be examined and discussed.

Learn More
Notice 23 Apr 2025 quality management, healthcare, assessment protocol, fda, drug manufacturing, regulations

🏭FDA Announces QMM Assessment Protocol Evaluation Program for Drug Manufacturers

The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for a limited number of drug manufacturing establishments to participate in the second year of the voluntary Quality Management Maturity Prototype Assessment Protocol Evaluation Program involving the use of a refined prototype assessment protocol to evaluate quality management maturity (QMM). The Center of Drug Evaluation and Research (CDER) implemented this voluntary program for manufacturers of CDER-regulated drug products to gain additional experience with, and further refine as necessary, the prototype assessment protocol and process, to help enable consistent and meaningful assessment of participating establishments' quality management practices, and to provide useful feedback to participants. This notice announces CDER's intent to continue the voluntary QMM Prototype Assessment Protocol Evaluation Program, outlines the types of establishments CDER is seeking for participation, and describes the process for submitting a request to participate in the program.

Learn More